OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	130
Current approach to muscle imaging in myositis	66
Editorial introduction	55
Urticarial vasculitis	50
Current views on lupus in children	44
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	38
Giant cell arteritis: update on pathogenesis and clinical implications	37
The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence	36
Axial spondyloarthritis guidelines – aiming for maximum impact	34
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden	32
Osteoporosis epidemiology using international cohorts	32
Editorial introductions	28
Optimizing reproductive health management in lupus and Sjogren's syndrome	27
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	26
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	26
The gut microbiota in spondyloarthritis: an update	25
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	25
Rheumatoid arthritis – the challenge of heterogeneity	25
Editorial introductions	24
Ribosome dysfunction in osteoarthritis	23
Updates on translational and clinical research in systemic sclerosis	22
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	22
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	20
Update on gout management: what is old and what is new	19
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	19

Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	18
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	18
Editorial introduction	18
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	18
Editorial introductions	18
Health inequities in the rheumatic diseases of childhood	17
Epidemiology of myositis	17
Defining and managing flares in axial spondyloarthritis	17
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	17
Animal models of vasculitis	16
Raynaud's phenomenon and digital ulcers: advances in evaluation and management	16
Editorial introductions	16
Biomarkers in systemic sclerosis: mechanistic insights into pathogenesis and treatment	15
Gout and the COVID-19 pandemic	14
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	14
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	14
New developments related to lung complications in pediatric rheumatic disease	13
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	13
Editorial introductions	13
Editorial introductions	13
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	13
Insights into origins and specificities of autoantibodies in systemic sclerosis	12
Biomarker discovery in psoriatic disease	12
Diagnosis and management of primary heart involvement in systemic sclerosis	12
Insights into the molecular landscape of osteoarthritis in human tissues	12
Investigating gout flares: beyond a definition	11
Management of postinfectious inflammatory arthritis	11
Editorial introduction	11
AI am the future: artificial intelligence in pediatric rheumatology	11
Vasculitis and the NLRP3 inflammasome	11
Polymyositis: does it really exist as a distinct clinical subset?	11
Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications	10
The association of Behçet's syndrome with HLA-B51 as understood in 2021	10
Exploring challenges in the management and treatment of inclusion body myositis	10
Emerging biologic therapies for systemic lupus erythematosus	10
Epidemiology of osteoarthritis: literature update 2022–2023	10
Heart involvement in systemic sclerosis: emerging concepts	10
The contribution of endothelial cells to tissue fibrosis	9
Update on streptococcal-associated rheumatic disease	9
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	9
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	9
Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies	9
Current management of giant cell arteritis and its complications	9
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	8
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	8
New therapies in anti-MDA5 antibody-positive dermatomyositis	8
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	8
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	8
Animal models in systemic sclerosis: an update	8
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	8

Update on muscle imaging in myositis	7
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	7
What are mice teaching us about psoriatic arthritis?	7
Bone in osteoarthritis: imaging and interventions	7
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	7
Calcinosis in systemic sclerosis	7
Takayasu arteritis	7
Anti-HMGCR myopathy: clinical and histopathological features, and prognosis	7
Biomarkers in juvenile idiopathic arthritis: towards precision diagnosis and personalized therapy?	7
Clinical endpoints in myositis: challenges and ways forward	6
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	6
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	6
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	6
Recent advances in immunometabolism in rheumatic diseases	6
Osteoarthritis gene therapy in 2022	6
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	6
Epidemiology of systemic vasculitis	6
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	6
Go or no-go for treat-to-target in axial spondyloarthritis?	6
Quo vadis reactive arthritis?	6
Contribution of keratinocytes to dermal fibrosis	5
Calcinosis in systemic sclerosis	5
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	5
Metabolic perturbations in systemic sclerosis	5
Rethinking spondyloarthritis: beyond lumping and splitting	5
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	5
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	5
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
Renal disease in pediatric rheumatology	5
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	5
Should CAR-T cells be used as monotherapy?	5
Updates in juvenile dermatomyositis: pathogenesis and therapy	4
Omics studies in Behçet's disease	4
Editorial introduction	4
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	4
Methods for objective assessment of skin involvement in systemic sclerosis	4
Editorial introduction	4
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	4
Disease modification in axial spondyloarthritis – still a controversy?	4
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	4
Regulatory T cells and systemic vasculitis	4
Differential diagnosis of necrotizing myopathy	4
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	4
Advances in understanding and examining lymphatic function: relevance for understanding autoimmunity	4
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	4
Advances in osteoarthritis imaging	4
Editorial myositis and myopathies	4
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	3
Novel therapies in juvenile idiopathic arthritis	3
Human genetics of Whipple's disease	3
Physical exercise for the management of systemic autoimmune myopathies: recent findings, and future perspectives	3
Drug therapy in juvenile spondyloarthritis	3
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	3
SGLT-2 inhibitors: new horizons for rheumatologists	3
A treat-to-target approach is needed for Behçet's syndrome	3
An update on topical therapies for psoriasis	3
Integrating genetic and social factors to understand health disparities in lupus	3
Is osteoarthritis a mitochondrial disease? What is the evidence	3
Understanding psoriatic disease at single-cell resolution: an update	3
Editorial introductions	3
An update on inflammation in antiphospholipid syndrome	3
Gastrointestinal manifestations of systemic sclerosis: current approaches and emerging therapies	3
Rheumatologic immune checkpoint inhibitor-related adverse events	3
The impact of omics research on our understanding of osteoarthritis and future treatments	3
Vaccination updates and special considerations for systemic lupus erythematosus patients	3
Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights	3